1. |
de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J]. J Clin Oncol, 2000, 18(16): 2938-2947.
|
2. |
Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer[J]. J Clin Oncol, 2000, 18(1): 136-147.
|
3. |
Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial[J]. Lancet, 2000, 355(9209): 1041-1047.
|
4. |
Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer[J]. N Engl J Med, 2005, 352: 476-487.
|
5. |
Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase Ⅲ study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer[J]. J Clin Oncol, 2008,26(12): 2006-2012.
|
6. |
Diaz-Rubio E, Tabernero J, Gomez-Espana A, et al. Phase Ⅲ study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial[J]. J Clin Oncol, 2007, 25(27): 4224-4230.
|
7. |
Ohtsu A, Baba H, Sakata Y, et al. PhaseⅡ study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma.[J]. Br J Cancer, 2000,83(2): 141-145.
|
8. |
Shirao K, Ohtsu A, Takada H, et al. PhaseⅡ study of oral S-1 for treatment of metastatic colorectal carcinoma[J]. Cancer, 2004, 100(11): 2355-2361.
|
9. |
Malik ST, Talbot D, Clarke PI, et al. PhaseⅡ trial of UFT in advanced colorectal and gastric cancer[J]. Br J Cancer, 1990, 62(6): 1023-1025.
|
10. |
Mathé G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum[J]. Biomed Pharmacother, 1989, 43(4): 237-250.
|
11. |
王艳荣,张芳.运用奥沙利铂联合化疗治疗大肠癌的观察及护理[J].现代护理,2001,7(10): 39.
|
12. |
罗丽莹,吕韶敏,刘文超.奥沙利铂联合氟尿嘧啶四氢叶酸治疗胃肠道恶性肿瘤43例[J].第四军医大学学报,2002,23(5): 475.
|
13. |
万以叶.草酸铂联合氟尿嘧啶、甲酰四氢叶酸治疗晚期大肠癌的疗效观察[J].中国癌症杂志,2001,11(6):566.
|
14. |
Fischel JL, Formento P, Ciccolini J, et al. Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity[J]. Br J Cancer, 2002, 86(7): 1162-1168.
|
15. |
Boisdron-Celle M,Craipeau C,Brienza S,et al,Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences[J]. Cancer Chemother Pharmacol,2002,49(3): 235-243.
|
16. |
Li J, Yin J, Zhu X, et al. PhaseⅠ dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer[J]. Anticancer Drugs, 2008, 19(7): 745-748.
|
17. |
Kim HS, Park MJ, Uhm JE, et al. A phaseⅠ trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer[J]. Int J Colorectal Dis, 2009, 24(11): 1311-1316.
|
18. |
Hong YS, Lee JL, Park JH, et al. PhaseⅠ study of preoperative chemoradiation with S-1 and oxaliplatin in patients with locally advanced resectable rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 79(3): 684-689.
|
19. |
Zang DY, Lee BH, Park HC, et al. PhaseⅡ study with oxaliplatin and S-1 for patients with metastatic colorectal cancer[J]. Ann Oncol, 2009, 20(5): 892-896.
|
20. |
Doi Y, Okada T, Matsumoto H, et al. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model[J]. Cancer Sci, 2010, 101(11): 2470-2475.
|
21. |
Hong J, Han SW, Ham HS, et al. PhaseⅡ study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis[J]. Cancer Chemother Pharmacol, 2011, 67(6): 1323-1331.
|